Unit 2.06/31 Lexington Drive, Bella Vista, NSW 2153 Ph: 1300 995 098 • www.cambium.bio • ABN 13 127 035 358 ASX Announcement 28 September 2026 Date of 2026 Annual General Meeting and closing date for director nominations Sydney, Australia, 28 September 2026: Cambium Bio Limited (ASX:CMB)...
Date of AGM and Closing Date for Director Nominations
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The AGM will be held online on a specified date and time. The closing date for director nominations is also provided, along with instructions for submission. Shareholders will receive a Notice of Meeting with further details in early October. Cambium Bio is focused on developing innovative biologics for ophthalmology and tissue repair applications.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
In the deck
Earlier from Cambium Bio
- Notification of cessation of securities - CMB
- Notification regarding unquoted securities - CMB
- Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease
- Cambium Bio Secures A$10.85 Million Funding Package
- Proposed issue of securities - CMB
Later from Cambium Bio
- Corporate Presentation - September 2026
- Notice of Annual General Meeting and Proxy form
- Access Letter and Online Meeting Guide
- Quarterly Activities/Appendix 4C Cash Flow Report
- Results of Annual General Meeting
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio